Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Pharmaceuticals

GSK and Epix sign drug discovery pact

December 18, 2006 | A version of this story appeared in Volume 84, Issue 51

GlaxoSmithKline and Epix Pharmaceuticals will join forces to develop small-molecule drugs against four G-protein-coupled receptors (GPCR), a broad class of molecular targets that convert signals received outside a cell into biological processes inside the cell. The deal includes Epix' 5-HT4 partial agonist program, which is in Phase II trials to treat Alzheimer's patients. GSK will take a $17.5 million stake in the Lexington, Mass.-based biotech firm, as part of a $35 million up-front fee. Epix could eventually rack up milestone payments of $1.2 billion based on the success of the GPCR programs.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.